Bijan Eghtesad, MD
Surgery · Cleveland, OHNPI 1144314618
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,524 of the $7,912 with a category attached, or 95.1%. Sanofi-aventis U.S. LLC accounts for 95.1% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2020 at $7,524 and has fallen 98.1% since, to $146 in 2023.
Across 5 payments — averaging $1582.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$8K
- Medtronic$149
- Dilon Technologies, Inc.$146
- Takeda Pharmaceuticals U.S.A., Inc.$93
Across 20 payments — averaging $20,510 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$299K
- Modernatx, Inc.$111K
What the payments were for
- Consulting fees$7,52495%
- Food & beverage$3885%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 1 | $7,524 |
| Medtronic | 2 | $149 |
| Dilon Technologies, Inc. | 1 | $146 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $93 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- THYMOGLOBULIN$7,524
- HemoBlast Bellows$146
How this compares
$7,912 in reported general payments places this provider in the 75th percentile of 988 surgery providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tacrolimus | 26 | $1,752 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 18 | $56 |
Paid to pharmacies, not to this prescriber.
Other surgery in Cleveland
- Raymond OndersCleveland$1.2M
- Neilendu KunduCleveland$808K
- Chase WehrleCleveland$741K
- Craig JarrettCleveland$622K
- Ihya GorgunCleveland$527K
- Gareth Morris-StiffCleveland$250K
- Alan SaberCleveland$204K
- Eren BerberCleveland$191K
- Leena KhaitanCleveland$187K
- Ali AminianCleveland$147K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.